STAGE IV PROSTATE CANCER AJCC V8

This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…

This study is testing whether combining two immunotherapy drugs, vidutolimod and nivolumab, can help the body's immune system find and kill prostate cancer cells that have spread. It is for men whose cancer has stopped responding to standard hormone therapy and chemotherapy. The …

This study is testing if a shorter, more intense course of radiation is safe and effective for men whose prostate cancer has returned or spread to a few lymph nodes. It compares two radiation methods—proton therapy and standard IMRT—to see which one causes fewer serious side effe…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study is testing whether adding an anti-inflammatory drug (golimumab) to a standard prostate cancer hormone blocker (apalutamide) can better control a very advanced form of the disease. It's for men whose cancer has spread and stopped responding to standard hormone treatment…

This early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …

This study is testing a multi-step treatment to control a fast-spreading and hard-to-treat form of prostate cancer. It will involve about 120 men whose cancer has spread and is resistant to standard hormone therapy. The goal is to see if combining chemotherapy, a drug that helps …

This study is testing whether a combination of three drugs can help control prostate cancer that has spread to other parts of the body. Researchers want to see if they can predict which patients will respond best to this treatment by analyzing tumor characteristics. The trial inv…

This study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…

This study is testing a personalized treatment method for people with advanced breast, prostate, ovarian, pancreatic, or sarcoma cancers that have spread. Doctors analyze each patient's tumor using genetic and protein tests to understand how the cancer is changing and which drugs…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better than a different standard combination (docetaxel + carboplatin) for men with advanced prostate cancer that has spread and is no longer responding to …

This study is testing if adding a drug called rucaparib to standard treatment (enzalutamide) works better for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer or keeps their cancer fro…

This study is testing whether men with advanced prostate cancer that has spread can safely take a break from hormone-blocking medications when their cancer responds exceptionally well to treatment. The trial involves 79 men who have been on strong hormone therapy for 18-24 months…